Evgeny Deforzh | Cancer | Best Researcher Award

Dr. Evgeny Deforzh | Cancer | Best Researcher Award

Brigham and Women’s Hospital, Harvard University | United States

Dr. Evgeny Deforzh is a molecular biologist whose work focuses on the regulation of RNA, microRNAs, chromatin dynamics, and their roles in cancer and neurological disease. After earning his B.S. and M.S. in Biology from Saint Petersburg State University and a Ph.D. in Molecular Biology from Paris‑Saclay University, he completed postdoctoral research as a Research Fellow and subsequently served as Instructor in Neurology at Brigham & Women’s Hospital. His peer‑reviewed contributions include insights into how WEE1 regulators switch roles in cell cycle control, protection of cyclin mRNAs from translational repression, the impact of glioblastoma‑derived extracellular vesicles on astrocyte transformation, and the nuclear modulation of splicing by oncogenic microRNAs. More recently, his work has elucidated promoter/enhancer RNA regulation of super‑enhancers, and miRNA pathways as therapeutic targets in gliomas and meningiomas. To date, Dr. Deforzh has published ~15–20 independent original research articles (first‑, co‑first, or senior‑author) with many additional co‐authored papers. His publications have been cited in the literature ~800‑1,200 times, giving him an approximate h‑index of 12–15. His research has advanced understanding of RNA regulatory networks in cancer and offers potential translational pathways for diagnostics and therapy.

Profiles: Google Scholar | Scopus

Featured Publications:

Zeng, A., Wei, Z., Rabinovsky, R., Jun, H. J., El Fatimy, R., Deforzh, E., & Arora, R. (2020). Glioblastoma-derived extracellular vesicles facilitate transformation of astrocytes via reprogramming oncogenic metabolism. iScience, 23(8), 101420.

Deforzh, E., Uhlmann, E. J., Das, E., Galitsyna, A., Arora, R., Saravanan, H., … (2022). Promoter and enhancer RNAs regulate chromatin reorganization and activation of miR-10b/HOXD locus, and neoplastic transformation in glioma. Molecular Cell, 82(10), 1894–1908.e5.

El Fatimy, R., Zhang, Y., Deforzh, E., Ramadas, M., Saravanan, H., Wei, Z., … (2022). A nuclear function for an oncogenic microRNA as a modulator of snRNA and splicing. Molecular Cancer, 21(1), 17.

Poller, W., Sahoo, S., Hajjar, R., Landmesser, U., & Krichevsky, A. M. (2023). Exploration of the noncoding genome for human-specific therapeutic targets—Recent insights at molecular and cellular level. Cells, 12(22), 2660.

Deforzh, E., Vargas, T. R., Kropp, J., Vandamme, M., Pinna, G., & Polesskaya, A. (2016). IMP-3 protects the mRNAs of cyclins D1 and D3 from GW182/AGO2-dependent translational repression. International Journal of Oncology, 49(6), 2578–2588.

Kratassiouk, G., Pritchard, L. L., Cuvellier, S., Vislovukh, A., Meng, Q., … (2016). The WEE1 regulators CPEB1 and miR-15b switch from inhibitor to activators at G2/M. Cell Cycle, 15(5), 667–677.

Sunila Pradeep | Ovarian Cancer | Women Researcher Award

Dr. Sunila Pradeep | Ovarian Cancer | Women Researcher Award

Dr. Sunila Pradeep | The Medical College of Wisconsin | United States

Dr. Sunila Pradeep, Ph.D., is an accomplished Associate Professor at the Medical College of Wisconsin, with over two decades of academic and research experience in immunology, oncology, and translational medicine. Originating from India, Dr. Pradeep began her journey in microbiology before delving deep into cancer research. Her multidisciplinary work bridges basic science with clinical relevance, particularly in ovarian and uterine cancers. Having trained in globally recognized institutions like the Weizmann Institute (Israel) and MD Anderson Cancer Center (USA), she has cultivated a robust research portfolio. Her impact in biomedical sciences is well-established. Dr. Pradeep’s ongoing work on extracellular vesicles, tumor microenvironment, and therapy resistance showcases her commitment to solving real-world clinical problems. A recipient of numerous national and international honors, she is a role model for aspiring women in science, blending scientific rigor with compassionate mentorship.

Publication Profile: 

Scopus

Education:

Dr. Sunila Pradeep’s academic path began in India, where she completed her B.Sc. and M.Sc. in Microbiology at Bharathiar University, Coimbatore, Tamil Nadu. Her passion for biomedical sciences led her to pursue a Ph.D. in Immunology at the University of Calicut, Kerala, under the mentorship of Dr. Girija Kuttan, where she began her exploration into natural compounds with anti-cancer properties. Her graduate studies laid a strong foundation in experimental biology and immunomodulation. Eager to expand her research horizons globally, she pursued postdoctoral training at the Weizmann Institute of Science in Israel, and later at the prestigious MD Anderson Cancer Center, Texas, USA, where she transitioned into translational cancer research. This diverse academic journey spanning three countries has given Dr. Pradeep a unique global perspective, rigorous research training, and an innovative approach to solving complex oncological challenges.

Professional Experience:

Dr. Sunila Pradeep has more than 18 years of research experience in oncology and immunology. Her professional career began with a Postdoctoral Fellowship at the Weizmann Institute, where she explored molecular signaling in cancer progression. She then advanced to a key fellowship role at the MD Anderson Cancer Center, focusing on therapeutic resistance in ovarian cancer. Since joining the Medical College of Wisconsin as an Associate Professor, she has established herself as a leading researcher in ovarian tumor microenvironments, metastasis mechanisms, and extracellular vesicle biology. Her role extends beyond research—she is also a dedicated mentor to graduate students and postdocs, and contributes to several multidisciplinary cancer initiatives. Dr. Pradeep’s scientific rigor, grant success, and translational insights have made her a sought-after collaborator. Her efforts to bridge laboratory research with clinical application reflect her commitment to improving outcomes for women suffering from gynecologic cancers.

Awards and Honors:

Dr. Pradeep’s distinguished career has been marked by several prestigious awards. She received the Fr. Gabriel Award from the Amala Institute of Medical Sciences, Kerala, recognizing her excellence in immunology research. During her tenure at MD Anderson Cancer Center, she was honored with the Trainee Excellence Award, reflecting her high-impact work in cancer biology. Her promising contributions to ovarian cancer research earned her the Scholar-in-Training Award from the Marsha Rivkin Center Foundation for Ovarian Cancer Research—a significant achievement for emerging leaders in gynecologic oncology. These accolades underscore her strong scientific foundation, innovation, and leadership in translational oncology. Beyond individual awards, her prolific publication record and active engagement in scientific communities amplify her impact. Dr. Pradeep’s recognition across three continents emphasizes her global footprint and her consistent commitment to advancing women’s health through science.

Research Focus:

Dr. Sunila Pradeep’s research revolves around understanding tumor biology, metastasis, angiogenesis, immunomodulation, and drug resistance in gynecologic cancers, particularly ovarian and uterine cancers. She investigates the role of extracellular vesicles, tumor-derived signals, and the tumor microenvironment in driving cancer progression and therapy evasion. Her lab explores novel biomarkers and targets for overcoming VEGF resistance, improving chemotherapy response, and modulating the immune system to suppress tumor growth. Her translational work includes identifying new combination therapies (e.g., selinexor with eribulin) and examining gut microbiota’s role in estrogen signaling—connecting metabolic and hormonal networks with cancer biology. She is also involved in cutting-edge research on RNA-binding proteins, such as FXR1, and their roles in mRNA translation in cancer. With cross-disciplinary collaborations and NIH-supported studies, her focus bridges fundamental discovery with real-world clinical applications. Her ultimate goal: to make therapies more precise, personalized, and effective for women with cancer.

Publications Top Notes: 

  1. Immunomodulatory and antitumor activity of Piper longum Linn. and piperine

  2. Protective effect of Piper longum fruit ethanolic extract on radiation-induced damages in mice

  3. Expression of VEGF and VEGF receptors in tumor angiogenesis and malignancies

  4. Protective effect of Thuja occidentalis against radiation-induced toxicity in mice

  5. Piper longum inhibits VEGF and proinflammatory cytokines and tumor-induced angiogenesis

  6. Antimetastatic activity of Thuja occidentalis in a mouse model

  7. Inhibition of carcinogenesis by homeopathic drugs

  8. Effect of homeopathic medicines on transplanted tumors in mice

  9. Dynamized preparations in cell culture

  10. Phosphomimetic mutants of PEDF with enhanced antiangiogenic activity as anticancer agents

Conclusion:

Overall, Dr. Sunila Pradeep is highly qualified and a strong candidate for a Best Researcher Award in ovarian cancer research. Her prolific publication record, substantial citation impact, and focus on innovative cancer biology and treatment research provide a solid foundation for recognition. By highlighting her leadership contributions, translational impact, and broader scientific engagement, she can further strengthen her nomination. Her work clearly advances the field of ovarian cancer and serves as a model for impactful biomedical research, making her a deserving contender for such a prestigious award.